Cargando…

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer

The present study evaluated the efficacy and safety of pemetrexed, carboplatin and bevacizumab, followed by maintenance pemetrexed and bevacizumab, in chemotherapy-naïve patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). The patients were administered pemetrexed (500 mg/m(2...

Descripción completa

Detalles Bibliográficos
Autores principales:	YOKOI, TAKASHI, TORII, YOSHITARO, KATASHIBA, YUICHI, SUGIMOTO, HIROYUKI, TANIJIRI, TSUTOMU, OGATA, MAKOTO, INAGAKI, NORIKO, KIBATA, KAYOKO, HAYASHI, MINA, NIKI, MAIKO, SHIMIZU, TOSHIKI, MIYARA, TAKAYUKI, KURATA, TAKAYASU, NOMURA, SHOSAKU
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4214444/ https://www.ncbi.nlm.nih.gov/pubmed/25364406 http://dx.doi.org/10.3892/ol.2014.2552

Ejemplares similares

Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation
por: Kurata, Takayasu, et al.
Publicado: (2017)

Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer
por: Nakaya, Aya, et al.
Publicado: (2017)

Retrospective analysis of bevacizumab‐induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer
por: Nakaya, Aya, et al.
Publicado: (2016)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2017)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2017)

Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer
por: SHIMIZU, TOSHIKI, et al.
Publicado: (2013)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
por: Kasai, Takashi, et al.
Publicado: (2023)

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
por: Niki, Maiko, et al.
Publicado: (2018)

Efficacy of Bevacizumab Combined with Pemetrexed in the Treatment of Recurrent and Metastatic Cervical Cancer
por: He, Ying, et al.
Publicado: (2022)

Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study
por: Nakano, Takashi, et al.
Publicado: (2020)

A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer
por: Liu, Ke-Jun, et al.
Publicado: (2015)

Pneumatosis Intestinalis in Lung Cancer Induced Twice by Different Drugs: Bevacizumab and Pemetrexed
por: Nunomiya, Keiko, et al.
Publicado: (2021)

Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation
por: Kader, Yasser Abdel, et al.
Publicado: (2013)

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
por: Jiang, Zhansheng, et al.
Publicado: (2018)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Carboplatin/pemetrexed: COVID-19 infection: 2 case reports
Publicado: (2021)

Carboplatin/pembrolizumab/pemetrexed: COVID-19 pneumonia: case report
Publicado: (2021)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

A Case of Lung Adenocarcinoma with Marked Improvement of Pulmonary Lymphangitic Carcinomatosis by Adding Bevacizumab to Cisplatin and Pemetrexed
por: Natsume, Maika, et al.
Publicado: (2017)

Sinus arrhythmia caused by pemetrexed with carboplatin combination: A case report
por: Quan, Xianghua, et al.
Publicado: (2022)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature
por: INAGAKI, NORIKO, et al.
Publicado: (2013)

Antiplatelet antibody may cause delayed transfusion-related acute lung injury
por: Torii, Yoshitaro, et al.
Publicado: (2011)

Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

Slowly developing toxic epidermal necrolysis-like reaction associated with pemetrexed and carboplatin
por: Eichhoff, Gerhard
Publicado: (2020)

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018)

Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review
por: Wang, Haiyong, et al.
Publicado: (2016)

Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed
por: Wei, Lai, et al.
Publicado: (2017)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
por: Li, Xin, et al.
Publicado: (2021)

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
por: KIBATA, KAYOKO, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_9a40fja9adu27jno5md92hsvqk